Back to top

Guggenheim Sticks to Their Buy Rating for Insmed (INSM)

Guggenheim analyst Vamil Divan reiterated a Buy rating on Insmed yesterday and set a price target of $207.00. The company’s shares closed yesterday...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Insmed, Inc. (INSM)